Form 4: Agenus Inc. Executive Receives Stock for Salary

Garo H. Armen, Director and Officer of Agenus Inc., received 4,925 shares of common stock valued at $3.30 per share as compensation for his salary.

Summary

• Garo H. Armen, a Director and Officer of Agenus Inc., received 4,925 shares of common stock on June 12, 2026.
• These shares were issued in lieu of cash salary, as approved by the Agenus Inc. Compensation Committee.
• The shares are fully vested upon issuance and were valued at the closing price of $3.30 per share on the transaction date.
• Following this transaction, Mr. Armen beneficially owns 360,892 shares of common stock, with 31,298 held indirectly in IRA accounts and 28,950 held indirectly through a GRAT and a partnership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports a standard executive compensation transaction rather than significant financial performance or strategic shifts.

Positives

• Executive compensation aligned with company stock, demonstrating management's commitment to the company's performance.
• Shares received are fully vested, providing immediate benefit to the reporting person.
• The transaction was conducted under an approved equity incentive plan.

Negatives

• The value of the stock received for salary is tied to the market price, which can fluctuate.
• The filing does not provide details on the total salary amount being converted to stock.

Risks

• The value of the executive's compensation is directly linked to the stock price, exposing him to market volatility.
• Indirect beneficial ownership through various entities introduces complexity in tracking ultimate beneficial interest.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a change in beneficial ownership.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.
• The shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

Industry Context

StockSavvy.ai notes that the use of stock as a form of executive compensation is a common practice in the biotechnology and pharmaceutical industries, aiming to align executive interests with shareholder value and conserve cash.

Related Party Transactions

• The transaction involves Garo H. Armen, a Director and Officer, receiving stock for his salary, which is a related party transaction approved by the Compensation Committee.

Stakeholder Impact

• Shareholders: The issuance of stock for salary dilutes existing share ownership slightly, but also aligns executive compensation with company performance.
• Employees: May signal a company culture that prioritizes equity-based incentives.
• Management: Garo H. Armen's compensation is directly tied to the company's stock performance.

Next Steps

• Continued reporting of changes in beneficial ownership as required by SEC regulations.

Key Dates

Keywords

Form 4, SEC Filing, Agenus Inc., AGEN, Garo H. Armen, Stock Compensation, Insider Trading, Beneficial Ownership, Executive Compensation